Literature DB >> 22033480

Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope.

Robyn L Stanfield1, Jean-Philippe Julien, Robert Pejchal, Johannes S Gach, Michael B Zwick, Ian A Wilson.   

Abstract

Antibody Z13e1 is a relatively broadly neutralizing anti-human immunodeficiency virus type 1 antibody that recognizes the membrane-proximal external region (MPER) of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Based on the crystal structure of an MPER epitope peptide in complex with Z13e1 Fab, we identified an unrelated protein, interleukin (IL)-22, with a surface-exposed region that is structurally homologous in its backbone to the gp41 Z13e1 epitope. By grafting the gp41 Z13e1 epitope sequence onto the structurally homologous region in IL-22, we engineered a novel protein (Z13-IL22-2) that contains the MPER epitope sequence for use as a potential immunogen and as a reagent for the detection of Z13e1-like antibodies. The Z13-IL22-2 protein binds Fab Z13e1 with a K(d) of 73 nM. The crystal structure of Z13-IL22-2 in complex with Fab Z13e1 shows that the epitope region is faithfully replicated in the Fab-bound scaffold protein; however, isothermal calorimetry studies indicate that Fab binding to Z13-IL22-2 is not a lock-and-key event, leaving open the question of whether conformational changes upon binding occur in the Fab, in Z13-IL-22, or in both.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22033480      PMCID: PMC3245871          DOI: 10.1016/j.jmb.2011.10.014

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  105 in total

1.  Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.

Authors:  Gilad Ofek; Krisha McKee; Yongping Yang; Zhi-Yong Yang; Jeff Skinner; F Javier Guenaga; Richard Wyatt; Michael B Zwick; Gary J Nabel; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

2.  An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120.

Authors:  Adi Moseri; Subramanyam Tantry; Yael Sagi; Boris Arshava; Fred Naider; Jacob Anglister
Journal:  Virology       Date:  2010-03-26       Impact factor: 3.616

3.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

Review 4.  Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22.

Authors:  Gregory F Sonnenberg; Lynette A Fouser; David Artis
Journal:  Nat Immunol       Date:  2011-05       Impact factor: 25.606

Review 5.  Recent advances in IL-22 biology.

Authors:  Lauren A Zenewicz; Richard A Flavell
Journal:  Int Immunol       Date:  2011-03       Impact factor: 4.823

6.  Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response.

Authors:  Jason Ho; Robert A Uger; Michael B Zwick; Mark A Luscher; Brian H Barber; Kelly S MacDonald
Journal:  Vaccine       Date:  2005-02-18       Impact factor: 3.641

7.  Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.

Authors:  Hengyu Xu; Likai Song; Mikyung Kim; Margaret A Holmes; Zane Kraft; George Sellhorn; Ellis L Reinherz; Leonidas Stamatatos; Roland K Strong
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

8.  Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications.

Authors:  Steve Bryson; Jean-Philippe Julien; Rosemary C Hynes; Emil F Pai
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

9.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies.

Authors:  Ji Wang; Pei Tong; Lu Lu; Leilei Zhou; Liling Xu; Shibo Jiang; Ying-hua Chen
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

View more
  12 in total

1.  Combining different design strategies for rational affinity maturation of the MICA-NKG2D interface.

Authors:  Samuel H Henager; Melissa A Hale; Nicholas J Maurice; Erin C Dunnington; Carter J Swanson; Megan J Peterson; Joseph J Ban; David J Culpepper; Luke D Davies; Lisa K Sanders; Benjamin J McFarland
Journal:  Protein Sci       Date:  2012-08-10       Impact factor: 6.725

Review 2.  How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.

Authors:  Marie Pancera; Anita Changela; Peter D Kwong
Journal:  Curr Opin HIV AIDS       Date:  2017-05       Impact factor: 4.283

Review 3.  Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.

Authors:  Julia L Hurwitz; Mattia Bonsignori
Journal:  Viral Immunol       Date:  2018-01-09       Impact factor: 2.257

4.  Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry.

Authors:  Mikyung Kim; Likai Song; James Moon; Zhen-Yu J Sun; Anna Bershteyn; Melissa Hanson; Derek Cain; Selasie Goka; Garnett Kelsoe; Gerhard Wagner; Darrell Irvine; Ellis L Reinherz
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

Review 5.  Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA.

Authors:  Jean-Philippe Julien; Peter S Lee; Ian A Wilson
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

6.  Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1.

Authors:  Shi-Hua Xiang
Journal:  Curr HIV Res       Date:  2013-09       Impact factor: 1.581

7.  A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens.

Authors:  Emmanuel Y Dotsey; Andrea Gorlani; Sampat Ingale; Chad J Achenbach; Donald N Forthal; Philip L Felgner; Johannes S Gach
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

8.  Stapled HIV-1 peptides recapitulate antigenic structures and engage broadly neutralizing antibodies.

Authors:  Gregory H Bird; Adriana Irimia; Gilad Ofek; Peter D Kwong; Ian A Wilson; Loren D Walensky
Journal:  Nat Struct Mol Biol       Date:  2014-11-24       Impact factor: 15.369

9.  Transplanting supersites of HIV-1 vulnerability.

Authors:  Tongqing Zhou; Jiang Zhu; Yongping Yang; Jason Gorman; Gilad Ofek; Sanjay Srivatsan; Aliaksandr Druz; Christopher R Lees; Gabriel Lu; Cinque Soto; Jonathan Stuckey; Dennis R Burton; Wayne C Koff; Mark Connors; Peter D Kwong; Peter D Kwon
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

Review 10.  Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology.

Authors:  John A Robinson
Journal:  J Pept Sci       Date:  2013-01-24       Impact factor: 1.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.